
Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune…

Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune…
Founded: 2021
Headquarters: Cambridge, Massachusetts
Core technology: Human immune organoids + AI and automation
Total disclosed funding: ≈ $25.6M (across pre-seed, seed, Series A)
Notable investors: Y Combinator; AIX Ventures; Refactor; Jeff Dean
Preclinical prediction for immunotherapy discovery; reducing drug failure rates due to poor translatability from animal models to humans.
2021
Biotechnology
Pre-seed round recorded in 2021
Seed round recorded Dec 20, 2022
21000000
Series A reported June 2025 (~$21M)
“Includes participation from Y Combinator and a mix of venture firms and individual/backing investors (examples reported: AIX Ventures, Refactor, Jeff Dean)”
At Parallel Bio, we are leveraging the human immune system to unlock safer, more effective drugs. We believe immunotherapies are the future of medicine, but their discovery is hindered by outdated models that fail to capture the complexity of the human immune system.
Our platform overcomes these challenges by combining best-in-class human immune organoids with massive scale and advanced computational methods, including AI and machine learning. This allows us to generate unprecedented, population-scale insights into human health and disease.
We can rapidly discover new drugs that we know will work in patients from the start and understand how they will perform across an entire population—something not possible with today's technology. This knowledge will allow us to engineer therapies that will work for as many people as possible, ensuring a safe and effective cure for everyone.
We are a fast-paced, venture-backed company at a pivotal moment of growth. Join us on our journey as we create new tools to push the boundaries of what is possible.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week
| Company |
|---|
The Role Our platform models human immune responses in structured tissue, not dissociated cells. What makes that valuable is not the tissue engineering - it is the ability to recognize what organized immune tissue is showing you that simpler systems cannot, and to design experiments whose outputs connect to decisions in drug development. This is a role where the quality of the questions you ask matters as much as the quality of the execution. The most common failure in platform biology is invisible: technically sound experiments that never ask a question only this system could answer.
We are looking for a scientist who understands how immune function emerges from tissue-level architecture, who has enough proximity to drug development to know what translatable evidence looks like, and who designs experiments that produce it. You will own the core experimental workflow: tissue culture, perturbation, and biological interpretation. You will also run experiments, execute partner studies, and grow into building a team of your own.
Who You Are
What You'll Do
Qualifications
Parallel Bio is an equal opportunity employer committed to fostering an inclusive and respectful workplace. We encourage applications from individuals of all backgrounds, regardless of age, gender, ethnicity, religion, disability, or sexual orientation. Compensation Range: $155K - $170K